股權激勵草案發布 健帆生物(300529.SZ)拉昇逼近漲停創歷史新高
格隆匯2月5日丨健帆生物今日跳空上漲,盤中最高漲19.34%至92.68元,創歷史新高,市值740億元。公司昨日發佈了2021年限制性股票激勵計劃草案,擬向公司董事、中高級管理人員、核心骨幹等授予750萬股限制性股票,約佔目前公司股本總額7.99億股的0.94%。其中,擬以38.98元/股授予第一類限制性股票75萬股(佔比10%);擬以77.18元/股(現價為77.66元/股)授予第二類限制性股票675萬股(佔比90%)。股票激勵計劃公佈後,華泰證券給予其買入評級,目標價104.16元;國金證券亦給予其買入評級。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.